Global Chronic Kidney Disease (CKD) Drugs Market to Reach $17.4 Billion by 2025 - Analysis By Drug Class & Geography - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report to their offering.

The global Chronic Kidney Disease (CKD) Drugs market was valued at US$ 12.4 Bn in 2016, and is expected to reach US$ 17.4 Bn by 2025, expanding at a CAGR of 3.9% from 2017 to 2025.

Chronic Kidney Disease (CKD) is also known as chronic kidney failure, characterized by gradual loss of kidney function. There are different types of medications available in market. Medicines cannot reverse CKD; however, they are used to treat complications and to slow further kidney damage. Factors such as rising incidence of cardiovascular disorders and diabetes, increasing geriatric population, significant unmet needs, promising pipeline molecules such as ABT-614 (Abbott Laboratories) and EOS789 (Chugai Pharmaceutical) and increasing prevalence of CKD would further drive the growth of CKD drugs market globally. However, preferable use of generic drugs and in some countries may negatively impacting the market growth.

Currently, CKD drugs market is dominated by North America, due to factors such as higher cost of medication, changing healthcare reimbursement environment and upsurge in funding by government agencies and private organizations in healthcare system driving the growth of CKD drugs market in North America.

Companies Mentioned:

  • Abbvie, Inc
  • Allergan Plc
  • Amgen Inc
  • Astrazeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Fibrogen
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc
  • Kissei Pharmaceutical Co., Ltd
  • Pfizer, Inc
  • Sanofi S.A
  • Teva Pharmaceutical Industries Ltd

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Chronic Kidney Disease (Ckd) Drugs Market Analysis

Chapter 4 Global Chronic Kidney Disease (Ckd) Drugs Market, by Drug Class

Chapter 5 Global Chronic Kidney Disease (Ckd) Drugs Market, by Geography

Chapter 6 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/59vgw7/global_chronic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs